GLP-1 Receptor Agonists: Encouraging Signals for Treating Alcohol Use Disorder

GLP-1 Receptor Agonists: Encouraging Signals for Treating Alcohol Use Disorder

Excessive alcohol use is a leading cause of preventable death in the USA, and the number of annual deaths from alcohol more than doubles the number from dr

Can Medicare Sustain Widespread Access to GLP-1 Therapies?

Expanding Medicare coverage for glucagon-like peptide 1 (GLP-1) receptor agonists could significantly reduce obesity-related health issues, but it also risks adding tens of billions in new costs, highlighting the need for smart policy strategies to ensure access, affordability, and long-term sustainability.